AKESO Aktie

 

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

HONG KONG, July 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been successfully enrolled in the registration Phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in first-line treatment for advanced......

Merger Creates Second-Largest Independent Occupational Medicine Provider in the U.S. with 42 Clinics Across California and ArizonaLOS ANGELES--(BUSINESS WIRE)--$manda #mergersandacquisitions--An affiliate of Angeles Equity Partners, LLC (“Angeles”), a private investment firm that partners with niche manufacturing, critical industrial services, and specialty distribution businesses, together with Kain Capital LLC (“Kain”), a private equity firm focused on healthcare services and healthcare technology companies, today announced the merger of Agile Occupational Medicine (“Agile”) and Akeso Occupational Health (“Akeso”). This strategic combination forms the nation's second-largest independent occupational medicine provider, with 42 locations across California and Arizona. The combination of Agile and Akeso unites two high-performing platforms with complementary clinic networks and a common commitment to delivering high-quality, efficient care that improves patient outcomes and supports employ...

At close, HSI dropped 153 pts or 0.6% to 23,916. HSTI dropped 17 pts or 0.3% to 5,216. HSCEI fell 39 pts or 0.5% to 8,609. Market turnover reached $267.81 billion.Active Heavyweights:MEITUAN (03690.HK) closed at $120.8, down 1.6%BABA (09988.HK) closed at $105.1, down 1%XIAOMI (01810.HK) closed at $57.5, down 1%TENCENT (00700.HK)......

At midday close, HSI dropped 148 pts or 0.6% to 23,921. HSTI dropped 24 pts or 0.5% to 5,209. HSCEI fell 36 pts or 0.4% to 8,611.Active Heavyweights:XIAOMI (01810.HK) closed at $57.4, down 1.2%MEITUAN (03690.HK) closed at $121.7, down 0.9%PING AN (02318.HK) closed at $49.7, down 0.8%HKEX (00388.HK) closed at $414.8, down 0.6%BAB......

There was HKD987.4 million and HKD22.7 million Southbound Trading net inflow to MEITUAN-W (03690.HK) and XIAOMI-W (01810.HK).There was HKD3.2 billion, HKD885.3 million and HKD739.9 million Southbound Trading net outflow from BABA-W (09988.HK), TENCENT (00700.HK) and AKESO (09926.HK).For Southbound Trading of Shanghai-Hong Kong S......

At close, HSI dropped 151 pts or 0.6% to 24,069. HSTI dropped 35 pts or 0.7% to 5,233. HSCEI fell 76 pts or 0.9% to 8,648. Market turnover reached $231.25 billion.Active Heavyweights:XIAOMI (01810.HK) closed at $58.1, down 3.4%BABA (09988.HK) closed at $106.2, down 2.9%MEITUAN (03690.HK) closed at $122.8, down 2.5%HKEX (00388.HK......

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's......

KGI listed its recommended equities in a press conference in late-June.XIAOMI-W (01810.HK) TENCENT (00700.HK) BABA-W (09988.HK) TRIP.COM-S (09961.HK) CATL (03750.HK) SPDR GOLD TRT (02840.HK) CHINA UNICOM (00762.HK) AKESO (09926.HK) AIA (01299.HK) Futu Holdings (FUTU.US) POP MART (09992.HK) CHINA RES POWER (00836.HK)LINK REIT (00......

HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced,......

HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of......

There was HKD1.1 billion, HKD930.1 million and HKD687.5 million Southbound Trading net inflow to MEITUAN-W (03690.HK), CSPC PHARMA (01093.HK) and AKESO (09926.HK).There was HKD1.1 billion, HKD625.3 million and HKD199.9 million Southbound Trading net outflow from XIAOMI-W (01810.HK), TENCENT (00700.HK) and POP MART (09992.HK).For......

AKESO (09926.HK) announced earlier that its HARMONi global trial with partner Summit Therapeutics (SMMT.US) demonstrated that data from China can be transferred globally, which is crucial for all Chinese biotech companies to license outside China, according to Jefferies' research report. While there are concerns about more s......

Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die Gesellschaft von der chinesischen Akeso einlizenziert hat, hinterließen mehr Fragezeichen als Antworten....

Chinese biotech firm Akeso, whose cancer drug has been hailed as breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics' Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9. Summit said on Friday that the US Food and Drug Administration (FDA)......

The H shares of pharma inclined today (29th). SINO BIOPHARM (01177.HK) advanced 5.5% to $4.42, while CSPC PHARMA (01093.HK) surged 11.6% after announcing its 1Q results. AKESO (09926.HK) leaped 4%, while WUXI APPTEC (02359.HK) swelled 6.6%. WUXI BIO (02269.HK) shot up 9.8%.The 2025 annual meeting of American Society of Clinical ......

There was HKD1.2 billion, HKD485.7 million and HKD201.7 million Southbound Trading net inflow to MEITUAN-W (03690.HK), AKESO (09926.HK) and SMIC (00981.HK).There was HKD310.5 million, HKD307 million and HKD120 million Southbound Trading net outflow from XIAOMI-W (01810.HK), TENCENT (00700.HK) and 3SBIO (01530.HK).For Southbound ......

Der US-Pharmakonzern zahlt 1,25 Milliarden US-Dollar, um sich die weltweiten Rechte an einem experimentellen Krebsmedikament der chinesischen 3SBio zu sichern. Das teilte das Unternehmen am Dienstag mit. Der Deal, der laut Analysten von Bernstein den bisherigen Rekord für chinesische Biotech-Lizenzverträge bricht, umfasst darüber hinaus potenzielle Meilensteinzahlungen von bis zu 4,8 Milliarden US-Dollar. Pfizer will zusätzlich 100 Millionen Dollar direkt in das in Hongkong börsennotierte Unternehmen investieren.. --- Die Aktie von 3SBio schoss in Hongkong um 52 Prozent nach oben – der stärkste Tagesgewinn in der Unternehmensgeschichte. Laut Rebecca Liang, Senior Analystin bei Bernstein, belegt der Pakt mit Pfizer die "zunehmende Innovationskraft des gesamten chinesischen Biotech-Sektors"..

The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes its use as a first-line treatment in combination with platinum-based chemotherapy, as well as a......

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic NSCLC Ivonescimab Collaborations Progressing in Multiple Solid Tumor Settings: MD Anderson Collaboration Begins Enrolling Two Clinical Trials; Additional ISTs Initiated and Enrolling Leadership Team Advanced with Appointment of Robert LaCaze as Chief Commercial Officer MIAMI--(BUSINESS WIRE)--$SMMT--Summit Therapeutics Inc...